Compare Incyte Corporation (INCY) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Tapestry, Inc. — how do they compare? Incyte Corporation trades at $120.48 (market cap $24.54B), while Tapestry, Inc. trades at $153.48 (market cap $32.44B). The key difference: Tapestry, Inc. is the larger of the two by market cap, and Tapestry, Inc. pays a 1% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | TPR | |
|---|---|---|
Market Cap | $24.54B | $32.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $164.78 |
52-Week Low | $81.61 | $95.69 |
Enterprise Value | $20.04B | $35.29B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
TPR trades at $164.78, up 1.49% with strong technical momentum and bullish moving averages. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.66 exceeding the $1.30 estimate. Analyst sentiment remains overwhelmingly positive with 31 buy ratings and a $190.33 consensus price target, representing 15.5% upside potential. Recent news highlights Tapestry's AI initiatives and strong brand momentum driving market share gains.
The outlook appears favorable given TPR's earnings beat streak and positive analyst coverage, though elevated valuation ratios (P/E 48.95, P/S 4.34) and recent net income margin compression from 12.23% to 2.61% warrant monitoring. Key risks include competitive pressures in luxury retail and potential macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
